Isolation, Identification and Characterization of Degradation Impurity of Atorvastatin in Fixed Dose Combination of Atorvastatin and Ezetimibe
Abstract
The objective of this study is to isolation and characterization of unknown degradation product of Atorvastatin calcium in combination formulation product with Ezetimibe by using modern techniques of separation and characterization. An unknown impurity is generating during a forced degradation study of Atorvastatin and Ezetimibe fixed-dose combination tablets. By using the gradient reversed-phase high-pressure liquid chromatographic method, unknown degradation impurity was detected and quantified in the range of 0.05% to 0.2% of Atorvastatin. The impurity was enriched by extreme oxidation degradation of Atorvastatin and isolated through preparative HPLC. The structure of the impurity was characterized by mass and NMR spectrum.
Keywords:
Atorvastatin calcium, Ezetimibe, HPLC, Mass, NMR, Degradation.DOI
https://doi.org/10.25004/IJPSDR.2019.110506References
Leiter LA, Bays H, Conard S, et al. Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. Am J Cardiol. 2008;102(11):1495-1501.
https://wenku.baidu.com/view/35a9708f9ec3d5bbfd0a74f3?pcf=2&re=view.
Filip K, Bańkowski K, Sidoryk K, et al. Physicochemical characterization of ezetimibe and its impurities. J Mol Struct. 2011; 991(1-3):162-170.
Kumar P, Ghosh A, Chaudhary M. Stability Indicating Method Development for Simultaneous Estimation of Ezetimibe and Atorvastatin in Pharmaceutical Formulations by RP-HPLC. Pharm Anal Acta. 2012;03(06):164.
Rajasekaran A, Sasikumar R, Dharuman J. Simultaneous RP-HPLC method for the stress degradation studies of atorvastatin calcium and ezetimibe in multicomponent dosage form. Ars Pharm. 2011;52(3):12-18.
Yusuf SM, Samparna S, Yallareddy K, Pavani B, Sivakala T. Analytical method development and validation of atorvastatin and clopidogrel in tablet dosage form by RP-HPLC. EJPMR 2017;4(4):553-558.
Kadav AA, Vora DN. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. J Pharm Biomed Anal. 2008;48(1):120-126.
Talluri MVNK, Kalyankar A, Ragampeta S. Synchronized separation of atorvastatin—an antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations. J Pharm Anal. 2012;2(4):285-292.
Suresh R, Manavalan R, Valliappan K. Developing and optimizing a validated RP-HPLC method for the analysis of amlodipine and ezetimibe with atorvastatin in pharmaceutical dosage forms applying response surface methodology. International Journal of Pharmacy and Pharmaceutical Sciences 2012; 4(3):550-558.
Londhe SV, Deshmukh RS, Mulgund SV, Jain KS. Development and Validation of a Reversed-phase HPLC Method for Simultaneous Determination of Aspirin, Atorvastatin Calcium and Clopidogrel Bisulphate in Capsules. Indian J. Pharm. Sci., 2011;73(1):23-29.
Hafez HM, Elshanawany AA, Abdelaziz LM, Mohram MS. Development of a Stability-Indicating HPLC Method for Simultaneous Determination of Amlodipine Besylate and Atorvastatin Calcium in Bulk and Pharmaceutical Dosage Form. Pharm Anal Acta. 2014; 5(9):316.
https://sg.inflibnet.ac.in/bitstream/10603/27294/7/07_chapter%202.pdf.
Dubey S, Kumar Pandey R, Shankar Shukla S. Impurity Profiling and Drug Characterization: Backdrop and Approach. Indo Am. J P Sci. 2018;(04):2499-2515.
Nigovic B, Mornar A, Sertic M. A Review of Current Trends and Advances in Analytical Methods for Determination of Statins: Chromatography and Capillary Electrophoresis. In: Chromatography - The Most Versatile Method of Chemical Analysis. InTech; 2012.
Gupta LK. Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method. Spectrochim Acta Part A Mol Biomol Spectrosc. 2012; 97:495-501.
Ertürk S, Sevinç Aktaş E, Ersoy L, Fıçıcıoğlu S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J Pharm Biomed Anal. 2003;33(5):1017-1023.
Sonje VM, Kumar L, Meena CL, et al. Atorvastatin Calcium. Profiles Drug Subst Excipients Relat Methodol. 2010;35:1-70.
Kumar KK, Rao CK. A Validated Stability Indicating RP-UPLC Method for Atrovastain Calcium. American Journal of Analytical Chemistry. 2012;3:392-399.
K. Gajjar A. Impurity Profiling: A Case Study of Ezetimibe. Open Conf Proc J. 2011;2(1):108-112.
Sistla R, Tata VSSK, Kashyap YV, Chandrasekar D, Diwan P V. Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J Pharm Biomed Anal. 2005;39(3-4):517-522.
Gajjar AK, Shah VD. Isolation and structure elucidation of major alkaline degradant of Ezetimibe. J Pharm Biomed Anal. 2011;55(1):225-22.
Published
Abstract Display: 821 
PDF Downloads: 1329 
